NDAORALSOLUTION
Approved
Jul 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 6h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TEZRULY is an oral solution formulation of terazosin, an alpha-1 adrenergic antagonist approved by the FDA on July 29, 2024. Terazosin is indicated for benign prostatic hyperplasia (BPH) and hypertension by relaxing smooth muscle in the prostate and blood vessels. The liquid formulation may offer improved tolerability and dosing flexibility compared to existing tablet formulations.
Growth14.4 years to LOE
As a newly approved formulation in the growth phase, TEZRULY offers near-term commercial ramp opportunities with a focused team building market presence against established generic alternatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin
Started Apr 2011
24 enrolled
Ejaculation
Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin
Started Mar 2007
23 enrolled
Hyperhidrosis
Career Relevance
TEZRULY represents an early-stage launch opportunity in a mature therapeutic category with strong IP protection through 2041. Professionals joining this team will focus on differentiation strategy, payer negotiation, and market share capture against established generics in a stable, non-complex disease area.
Brand Manager
Worked on TEZRULY at Agepha Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.